<DOC>
	<DOCNO>NCT02354898</DOCNO>
	<brief_summary>This open-label , multicenter , phase 1 dose escalation study BBI503 monotherapy , BBI503 combination Sorafenib . This study population adult patient advance solid tumor monotherapy , adult patient advance hepatocellular carcinoma combination therapy .</brief_summary>
	<brief_title>A Study BBI503 Advanced Solid Tumors , BBI503/ Sorafenib Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Provision write informed consent . ≥ 20 year age Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Male female patient childproducing potential must agree use contraception avoidance pregnancy measure study 30 day last BBI503 dose Females childbearing potential must negative serum pregnancy test Adequate organ function Life expectancy ≥ 3 month Any know symptomatic untreated brain metastasis Pregnant breastfeed Crohn 's disease , ulcerative colitis extensive gastric small intestine resection Unable unwilling swallow BBI503 daily Uncontrolled concurrent disease Received investigational drug within 4 week prior first dose Prior treatment BBI503</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>